Scientists from the Anglo-German company, Cellzome, have reported that methodology known as chemoproteomics can show how drugs that are designed to inhibit epigenetic targets interact with molecular complexes not just single proteins.
Scientists from the Anglo-German company, Cellzome, have reported that methodology known as chemoproteomics can show how drugs that are designed to inhibit epigenetic targets interact with molecular complexes not just single proteins.